AIM ImmunoTech Inc. Common Stock AIM 深 沪
已收盘 07-02 16:00:00 美东时间
0.28
-0.016
-5.41%
华盛通- 最 高0.3083
- 今 开0.30
- 成交量 98.29万股
- 最 低 0.28
- 昨 收 0.296
- 总市值 776.28万
- 52周最高 20.3297
- 市盈率 静 --
- 换手率 3.55%
- 52周最低 0.21
- 委 比 0.00%
- 总股本 2772.42万
- 历史最高 20.3297
- 量 比 0.67
- 振 幅 9.56%
- 历史最低 0.21
- 每 手 1
- 风险率 2.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech Inc. announced the completion of enrollment in its Phase 2 DURIPANC trial combining Ampligen® with Imfinzi® for metastatic pancreatic cancer. The trial's primary endpoint, Clinical Benefit Rate, is expected to be analyzed by December 2026, with top-line results anticipated in Q1 2027. Secondary endpoints include overall survival, progression-free survival, and immune profiling. The company aims to use biomarker data to design a Pha...
06-18 13:01
AIM ImmunoTech Regains NYSE American Listing Compliance
The latest announcement is out from AIM ImmunoTech ( ($AIM) ). On June 12, 2026...
06-15 20:36
AIM ImmunoTech announces $2.65M financing priced at-market
AIM ImmunoTech (AIM) on Tuesday said it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gros...
06-09 21:54
AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 Shares
This prospectus relates to the offering and resale by the Selling Stockholders listed herein of up to an aggregate of 31,287,933 shares of our common stock, par value $0.001 per share (the "Common Stock"),
06-09 04:09
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
AIM ImmunoTech posts updated Ebola-focused investor presentation on website
AIM ImmunoTech posts updated Ebola-focused investor presentation on website AIM ImmunoTech published an Ebola-focused corporate presentation on Ampligen’s antiviral research, immune-modulating mechanism, preparedness positioning, and IV or intranasal human safety studies. The materials highlight pre
06-04 20:59
3 Penny Stocks Drawing Market Attention, 6/2/26
Hitek Global ($HKIT), Sphere 3D ($ANY), and AIM ImmunoTech ($AIM) are the three...
06-03 01:36
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
06-01 20:43
AIM ImmunoTech to host virtual investor segment on Ampligen’s Ebola opportunity
AIM ImmunoTech to host virtual investor segment on Ampligen’s Ebola opportunity AIM ImmunoTech will host a virtual investor segment titled “Ebola: What This Means” on June 4, 2026 at 9:00 a.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intel
05-27 20:47
